Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saul N Faust

Showing results (211-220 of 225) with videos related to

Pageof 23
Sort By:
The Journal of Infection|April 13, 2023
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]Xinxue Liu, Alasdair Ps Munro, Shuo Feng, et al.
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|February 8, 2020
Executive Summary: Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in ChildrenScott L Weiss, Mark J Peters, Waleed Alhazzani, et al.
Intensive Care Medicine|February 8, 2020
Executive summary: surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in childrenScott L Weiss, Mark J Peters, Waleed Alhazzani, et al.
The Journal of Allergy and Clinical Immunology|August 25, 2016
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort studyTanya I Coulter, Anita Chandra, Chris M Bacon, et al.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
Intensive Care Medicine|February 8, 2020
Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in childrenScott L Weiss, Mark J Peters, Waleed Alhazzani, et al.
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|February 8, 2020
Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in ChildrenScott L Weiss, Mark J Peters, Waleed Alhazzani, et al.
The Journal of Infection|April 21, 2023
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Annie Wright, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Lancet (London, England)|November 22, 2020
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialMaheshi N Ramasamy, Angela M Minassian, Katie J Ewer, et al.
Pageof 23

Showing results (211-220 of 225) with videos related to

Sort By:
Pageof 23
The Journal of Infection|April 13, 2023
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]Xinxue Liu, Alasdair Ps Munro, Shuo Feng, et al.
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|February 8, 2020
Executive Summary: Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in ChildrenScott L Weiss, Mark J Peters, Waleed Alhazzani, et al.
Intensive Care Medicine|February 8, 2020
Executive summary: surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in childrenScott L Weiss, Mark J Peters, Waleed Alhazzani, et al.
The Journal of Allergy and Clinical Immunology|August 25, 2016
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort studyTanya I Coulter, Anita Chandra, Chris M Bacon, et al.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
Intensive Care Medicine|February 8, 2020
Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in childrenScott L Weiss, Mark J Peters, Waleed Alhazzani, et al.
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|February 8, 2020
Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in ChildrenScott L Weiss, Mark J Peters, Waleed Alhazzani, et al.
The Journal of Infection|April 21, 2023
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Annie Wright, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Lancet (London, England)|November 22, 2020
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialMaheshi N Ramasamy, Angela M Minassian, Katie J Ewer, et al.
Pageof 23